Title:
NEW SIALYLTRANSFERASES FOR IN VIVO SYNTHESIS OF 3'SL
Document Type and Number:
Japanese Patent JP2023154004
Kind Code:
A
Abstract:
To provide production of sialylated Human Milk Oligosaccharides (HMOs), in particular biosynthetic production of 3'-sialyllactose (3'SL), and to provide genetically modified cells suitable for use in the production.SOLUTION: Provided is a genetically modified cell comprising a recombinant nucleic acid sequence encoding an enzyme having α-2,3-sialyltransferase activity, the enzyme being Clari1 comprising or consisting of a particular amino acid sequence or an amino acid sequence having at least 90% identity to the sequence; PmN comprising or consisting of a second specific amino acid sequence or an amino acid sequence having at least 90% identity to the sequence; or Neigon comprising or consisting of a third specific amino acid sequence or an amino acid sequence having at least 90% identity to the sequence, and the cells being genetically modified cells that produce sialylated HMOs.SELECTED DRAWING: None
More Like This:
| WO/2001/002587 | NOVEL ANTIFUNGAL AGENTS AND FUNGICIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
| JP7116399 | Anti-core fucosylated human immunoglobulin G antibody |
| WO/2005/066347 | PROTEINS |
Inventors:
MANOS PAPADAKIS
Application Number:
JP2023129889A
Publication Date:
October 18, 2023
Filing Date:
August 09, 2023
Export Citation:
Assignee:
DSM IP ASSETS BV
International Classes:
C12N15/54; C12N1/15; C12N1/19; C12N1/21; C12P19/04
Attorney, Agent or Firm:
Ikeda Adult
Yoshinori Shimizu
Junichiro Sakamaki
Yoshinori Shimizu
Junichiro Sakamaki